GB201217704D0 - Therapeutic agents - Google Patents
Therapeutic agentsInfo
- Publication number
- GB201217704D0 GB201217704D0 GBGB1217704.4A GB201217704A GB201217704D0 GB 201217704 D0 GB201217704 D0 GB 201217704D0 GB 201217704 A GB201217704 A GB 201217704A GB 201217704 D0 GB201217704 D0 GB 201217704D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- therapeutic agents
- therapeutic
- agents
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Priority Applications (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1217704.4A GB201217704D0 (en) | 2012-10-03 | 2012-10-03 | Therapeutic agents |
| JP2015535015A JP6184501B2 (ja) | 2012-10-03 | 2013-10-02 | 治療的に活性なオキサゾリン誘導体 |
| CA 2886265 CA2886265A1 (en) | 2012-10-03 | 2013-10-02 | Therapeutically active oxazoline derivatives |
| US14/432,842 US9382263B2 (en) | 2012-10-03 | 2013-10-02 | Therapeutically active oxazoline derivatives |
| EP13776992.3A EP2903990B1 (en) | 2012-10-03 | 2013-10-02 | Therapeutically active oxazoline derivatives |
| RU2015116643A RU2656209C2 (ru) | 2012-10-03 | 2013-10-02 | Терапевтически активные производные оксазолина |
| CN201380061725.5A CN104936962B (zh) | 2012-10-03 | 2013-10-02 | 治疗活性的噁唑啉衍生物 |
| BR112015007503A BR112015007503A2 (pt) | 2012-10-03 | 2013-10-02 | derivados de oxazolina terapeuticamente ativos |
| PCT/EP2013/070600 WO2014053581A1 (en) | 2012-10-03 | 2013-10-02 | Therapeutically active oxazoline derivatives |
| ES13776992.3T ES2639293T3 (es) | 2012-10-03 | 2013-10-02 | Derivados de oxazolina terapéuticamente activos |
| IN3751DEN2015 IN2015DN03751A (enExample) | 2012-10-03 | 2013-10-02 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1217704.4A GB201217704D0 (en) | 2012-10-03 | 2012-10-03 | Therapeutic agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB201217704D0 true GB201217704D0 (en) | 2012-11-14 |
Family
ID=47225621
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GBGB1217704.4A Ceased GB201217704D0 (en) | 2012-10-03 | 2012-10-03 | Therapeutic agents |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9382263B2 (enExample) |
| EP (1) | EP2903990B1 (enExample) |
| JP (1) | JP6184501B2 (enExample) |
| CN (1) | CN104936962B (enExample) |
| BR (1) | BR112015007503A2 (enExample) |
| CA (1) | CA2886265A1 (enExample) |
| ES (1) | ES2639293T3 (enExample) |
| GB (1) | GB201217704D0 (enExample) |
| IN (1) | IN2015DN03751A (enExample) |
| RU (1) | RU2656209C2 (enExample) |
| WO (1) | WO2014053581A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10526341B2 (en) | 2014-11-19 | 2020-01-07 | Memorial Sloan-Kettering Cancer Center | Thienopyrimidines and uses thereof |
| TWI703150B (zh) * | 2015-06-04 | 2020-09-01 | 美商庫拉腫瘤技術股份有限公司 | 用於抑制ｍｅｎｉｎ及ｍｌｌ蛋白之交互作用的方法及組合物 |
| GB201517263D0 (en) | 2015-09-30 | 2015-11-11 | Ucb Biopharma Sprl And Katholieke Universiteit Leuven | Therapeutic agents |
| GB201521767D0 (en) | 2015-12-10 | 2016-01-27 | Ucb Biopharma Sprl And Katholieke Universiteit Leuven K U Leuven R&D | Therapeutic agents |
| EP3429591B1 (en) | 2016-03-16 | 2023-03-15 | Kura Oncology, Inc. | Substituted thieno[2,3-d]pyrimidine derivatives as inhibitors of menin-mll and methods of use |
| US11944627B2 (en) | 2017-03-24 | 2024-04-02 | Kura Oncology, Inc. | Methods for treating hematological malignancies and Ewing's sarcoma |
| US11542248B2 (en) | 2017-06-08 | 2023-01-03 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with MLL proteins |
| TW201920170A (zh) | 2017-09-20 | 2019-06-01 | 美商庫拉腫瘤技術股份有限公司 | 經取代之menin-mll 抑制劑及使用方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1274708A1 (en) * | 2000-04-17 | 2003-01-15 | Basf Aktiengesellschaft | Herbicidal 3-heterocyclic substituted benzisothiazole and benzisoxazole compounds |
| EP1675861B1 (en) * | 2003-08-29 | 2015-12-23 | Vernalis (R&D) Ltd. | Pyrimidothiophene compounds |
| US20080200475A1 (en) * | 2005-03-28 | 2008-08-21 | Pfizer Inc. | 4-Piperazinothieno[2,3-D] Pyrimidine Compounds As Platelet Aggregation Inhibitors |
| AU2009291783A1 (en) * | 2008-09-10 | 2010-03-18 | Alcon Research, Ltd | Aminopyrimidine inhibitors of histamine receptors for the treatment of disease |
| CA2754890C (en) * | 2009-03-13 | 2018-01-16 | Piet Herdewijn | Bicyclic heterocycles |
| CA2773131C (en) * | 2009-09-04 | 2015-07-14 | The Regents Of The University Of Michigan | Compositions and methods for treatment of leukemia |
| GB201012889D0 (en) | 2010-08-02 | 2010-09-15 | Univ Leuven Kath | Antiviral activity of novel bicyclic heterocycles |
| GB201015411D0 (en) | 2010-09-15 | 2010-10-27 | Univ Leuven Kath | Anti-cancer activity of novel bicyclic heterocycles |
| GB201114212D0 (en) * | 2011-08-18 | 2011-10-05 | Ucb Pharma Sa | Therapeutic agents |
| GB201119401D0 (en) * | 2011-11-10 | 2011-12-21 | Ucb Pharma Sa | Therapeutic agents |
-
2012
- 2012-10-03 GB GBGB1217704.4A patent/GB201217704D0/en not_active Ceased
-
2013
- 2013-10-02 EP EP13776992.3A patent/EP2903990B1/en active Active
- 2013-10-02 JP JP2015535015A patent/JP6184501B2/ja not_active Expired - Fee Related
- 2013-10-02 US US14/432,842 patent/US9382263B2/en not_active Expired - Fee Related
- 2013-10-02 RU RU2015116643A patent/RU2656209C2/ru not_active IP Right Cessation
- 2013-10-02 WO PCT/EP2013/070600 patent/WO2014053581A1/en not_active Ceased
- 2013-10-02 IN IN3751DEN2015 patent/IN2015DN03751A/en unknown
- 2013-10-02 CA CA 2886265 patent/CA2886265A1/en not_active Abandoned
- 2013-10-02 ES ES13776992.3T patent/ES2639293T3/es active Active
- 2013-10-02 BR BR112015007503A patent/BR112015007503A2/pt not_active Application Discontinuation
- 2013-10-02 CN CN201380061725.5A patent/CN104936962B/zh not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2886265A1 (en) | 2014-04-10 |
| US9382263B2 (en) | 2016-07-05 |
| ES2639293T3 (es) | 2017-10-26 |
| RU2015116643A (ru) | 2016-11-27 |
| CN104936962A (zh) | 2015-09-23 |
| RU2656209C2 (ru) | 2018-06-01 |
| BR112015007503A2 (pt) | 2017-07-04 |
| EP2903990A1 (en) | 2015-08-12 |
| JP2015531388A (ja) | 2015-11-02 |
| CN104936962B (zh) | 2017-02-22 |
| JP6184501B2 (ja) | 2017-08-23 |
| EP2903990B1 (en) | 2017-06-14 |
| WO2014053581A1 (en) | 2014-04-10 |
| IN2015DN03751A (enExample) | 2015-10-02 |
| US20150274748A1 (en) | 2015-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB201212513D0 (en) | Therapeutic agents | |
| IL233756A0 (en) | New treatment factors | |
| ZA201305897B (en) | Combination therapy | |
| GB201321736D0 (en) | Therapeutic agents | |
| GB201321729D0 (en) | Therapeutic agents | |
| GB201321733D0 (en) | Therapeutic agents | |
| GB201321728D0 (en) | Therapeutic agents | |
| GB201321730D0 (en) | Therapeutic agents | |
| GB201114212D0 (en) | Therapeutic agents | |
| GB201321734D0 (en) | Therapeutic Agents | |
| GB201321732D0 (en) | Therapeutic agents | |
| ZA201400120B (en) | Combination therapy | |
| EP2867209A4 (en) | COMPOUNDS AND THEIR THERAPEUTIC USES | |
| GB201119401D0 (en) | Therapeutic agents | |
| GB201217439D0 (en) | Combination therapy | |
| GB201321735D0 (en) | Therapeutic Agents | |
| GB201910190D0 (en) | Optimised subsutaneous therapeutic agents | |
| GB201321731D0 (en) | Therapeutic agents | |
| GB201217704D0 (en) | Therapeutic agents | |
| GB201207305D0 (en) | Therapy | |
| EP2701744A4 (en) | COMBINATION THERAPY | |
| GB201420971D0 (en) | Therapeutic composition | |
| EP2879707A4 (en) | COMBINATION THERAPY | |
| IL217807A0 (en) | Therapeutic compositions | |
| EP2804853A4 (en) | THERAPEUTIC USES |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AT | Applications terminated before publication under section 16(1) |